SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, marks today one of the Company's most important milestones to date. The U.S. Patent and Trademark Office has granted it a new patent - U.S. Patent No. 11,207,290.
On speaking to the media, Adi Zuloff-Shani, PhD, Chief Technologies Officer of SciSparc, said "As an innovative pharmaceutical company, our IP portfolio is one of our greatest and most important assets. Obtaining a U.S. patent for our core technology constitutes a major achievement for us, especially as we are one of the few companies in the field that has IP protection on compounds and not only indications. He further added “We are pleased that the U.S. Patent and Trademark Office has again recognized the uniqueness of our compounds and methodologies and granted this patent."
This patent further strengthens the Company's intellectual property portfolio and protection of its core technologies, and in one of the most important markets in the world.
This is SciSparc's fourth granted patent in the U.S. Recently, the Company announced it has been granted the same patent in Australia and Japan.
Dr. Zuloff-Shani added, "Our growing portfolio of patents is a testament to the dedication and innovation of the SciSparc team and strengthens our commitment to continue the work we do to bring therapies to patients suffering from the challenges associated with disorders of the central nervous system, for whom there is currently no effective treatment."
About SciSparc (NASDAQ: SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is on creating and enhancing a portfolio of technologies. With this focus, the Company is currently engaged in the following drug development programs, SCI-110 for the treatment of Tourette Syndrome and for the treatment of obstructive sleep apnea; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy.
For more information, visit: scisparc.com, send an email to IR@scisparc.com, or call +972-3-6167055
Disclaimer: The products mentioned are THC-free and/or compliant with the 2018 Farm Bill. This article is purely for informational purposes and is not a recommendation in any way to buy or sell stocks.
Media Contact
Company Name: SciSparc Ltd.
Contact Person: Investor Relations
Email: Send Email
Phone: +972-3-6167055
Country: Israel
Website: scisparc.com
